Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum

Hsuan-Wei Chen,1 Jung-Chun Lin,1 Ying-Hsuen Wu,2,3,* Yi-Lin Chiu4,* 1Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 2Department of Ophthalmology, China Medical University Hospital, China Medical University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chen HW, Lin JC, Wu YH, Chiu YL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	xanthelasma xanthoma fatty liver nash nafld Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/5d1086d9b8994a96aebab9f846924c9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5d1086d9b8994a96aebab9f846924c9c
record_format	dspace
spelling	oai:doaj.org-article:5d1086d9b8994a96aebab9f846924c9c2021-12-02T14:41:40ZRisk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum1178-7031https://doaj.org/article/5d1086d9b8994a96aebab9f846924c9c2021-05-01T00:00:00Zhttps://www.dovepress.com/risk-of-non-alcoholic-fatty-liver-disease-in-xanthelasma-palpebrarum-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Hsuan-Wei Chen,1 Jung-Chun Lin,1 Ying-Hsuen Wu,2,3,* Yi-Lin Chiu4,* 1Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 2Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung City, Taiwan; 3School of Medicine, College of Medicine, China Medical University, Taichung City, Taiwan; 4Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan*These authors contributed equally to this workCorrespondence: Yi-Lin ChiuDepartment of Biochemistry, National Defense Medical Center, Taipei, TaiwanEmail yc566@georgetown.eduYing-Hsuen WuDepartment of Ophthalmology, China Medical University Hospital, China Medical University Email amywu0414@gmail.comBackground: Xanthelasma palpebrarum (XP) is a sign of hyperlipidemia and is closely linked to atherosclerosis. Since fatty liver shares similar risk factors with atherosclerosis, we hypothesized that patients with XP are also at risk of non-alcoholic fatty liver disease (NAFLD).Methods: In this retrospective cohort study, 37 patients with XP were compared with sex- and age-matched controls undergoing general health examination. Moreover, demographic information and lipid profiles were compared. The risk of NAFLD was evaluated using the hepatic steatosis and ZJU indices. In addition, we analyzed publicly available RNA sequencing data from the GSE48452 and GSE61260 datasets in the Gene Expression Omnibus database.Findings: Patients with XP had higher scores of hepatic steatosis index (37 ± 1.13 vs 32 ± 0.82, p=0.0006) and ZJU index (38.77 ± 1.0 vs 33.88 ± 0.74, p=0.0002). In addition, they had higher levels of lipid parameters, including total cholesterol, low-density lipoprotein (LDL), and fasting glucose. Among patients with fatty liver, individuals presenting with XP showed higher serum levels of total cholesterol (216 ± 10.4 vs 188.9 ± 7.6, p=0.04), fasting glucose (117.1 ± 6.4 vs 98.3 ± 2.4, p=0.002), and low-density lipoprotein (145.1 ± 8.7 vs 115.6 ± 6.4, p=0.009) than those without XP. In gene expression analysis, individuals presenting with non-alcoholic steatohepatitis showed higher Z scores of xanthelasma than those without non-alcoholic steatohepatitis.Conclusion: Our results suggest that individuals with XP have a higher risk of progression to NAFLD and develop a more severe dyslipidemia.Keywords: xanthelasma, xanthoma, fatty liver, NASH, NAFLDChen HWLin JCWu YHChiu YLDove Medical Pressarticlexanthelasmaxanthomafatty livernashnafldPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 1891-1899 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	xanthelasma xanthoma fatty liver nash nafld Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	xanthelasma xanthoma fatty liver nash nafld Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Chen HW Lin JC Wu YH Chiu YL Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
description	Hsuan-Wei Chen,1 Jung-Chun Lin,1 Ying-Hsuen Wu,2,3,* Yi-Lin Chiu4,* 1Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 2Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung City, Taiwan; 3School of Medicine, College of Medicine, China Medical University, Taichung City, Taiwan; 4Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan*These authors contributed equally to this workCorrespondence: Yi-Lin ChiuDepartment of Biochemistry, National Defense Medical Center, Taipei, TaiwanEmail yc566@georgetown.eduYing-Hsuen WuDepartment of Ophthalmology, China Medical University Hospital, China Medical University Email amywu0414@gmail.comBackground: Xanthelasma palpebrarum (XP) is a sign of hyperlipidemia and is closely linked to atherosclerosis. Since fatty liver shares similar risk factors with atherosclerosis, we hypothesized that patients with XP are also at risk of non-alcoholic fatty liver disease (NAFLD).Methods: In this retrospective cohort study, 37 patients with XP were compared with sex- and age-matched controls undergoing general health examination. Moreover, demographic information and lipid profiles were compared. The risk of NAFLD was evaluated using the hepatic steatosis and ZJU indices. In addition, we analyzed publicly available RNA sequencing data from the GSE48452 and GSE61260 datasets in the Gene Expression Omnibus database.Findings: Patients with XP had higher scores of hepatic steatosis index (37 ± 1.13 vs 32 ± 0.82, p=0.0006) and ZJU index (38.77 ± 1.0 vs 33.88 ± 0.74, p=0.0002). In addition, they had higher levels of lipid parameters, including total cholesterol, low-density lipoprotein (LDL), and fasting glucose. Among patients with fatty liver, individuals presenting with XP showed higher serum levels of total cholesterol (216 ± 10.4 vs 188.9 ± 7.6, p=0.04), fasting glucose (117.1 ± 6.4 vs 98.3 ± 2.4, p=0.002), and low-density lipoprotein (145.1 ± 8.7 vs 115.6 ± 6.4, p=0.009) than those without XP. In gene expression analysis, individuals presenting with non-alcoholic steatohepatitis showed higher Z scores of xanthelasma than those without non-alcoholic steatohepatitis.Conclusion: Our results suggest that individuals with XP have a higher risk of progression to NAFLD and develop a more severe dyslipidemia.Keywords: xanthelasma, xanthoma, fatty liver, NASH, NAFLD
format	article
author	Chen HW Lin JC Wu YH Chiu YL
author_facet	Chen HW Lin JC Wu YH Chiu YL
author_sort	Chen HW
title	Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
title_short	Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
title_full	Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
title_fullStr	Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
title_full_unstemmed	Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
title_sort	risk of non-alcoholic fatty liver disease in xanthelasma palpebrarum
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/5d1086d9b8994a96aebab9f846924c9c
work_keys_str_mv	AT chenhw riskofnonalcoholicfattyliverdiseaseinxanthelasmapalpebrarum AT linjc riskofnonalcoholicfattyliverdiseaseinxanthelasmapalpebrarum AT wuyh riskofnonalcoholicfattyliverdiseaseinxanthelasmapalpebrarum AT chiuyl riskofnonalcoholicfattyliverdiseaseinxanthelasmapalpebrarum
_version_	1718389872107978752

Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum

Ejemplares similares